Cost-Utility Analysis of Drug Treatments in Patients with Polypoidal Choroidal Vasculopathy in Thailand

References

• Cheung CMG, Lai TYY, Ruamviboonsuk P, et al. Polypoidal choroidal vasculopathy. Ophthalmology. 2018;125(5):708–724. doi:10.1016/j.ophtha.2017.11.019
   PubMed Web of Science ®Google Scholar
• Brown MM, Brown GC, Sharma S, Busbee B. Quality of life associated with visual loss: a time tradeoff utility analysis comparison with medical health states. Ophthalmology. 2003;110(6):1076–1081. doi:10.1016/S0161-6420(03)00254-9
   PubMed Web of Science ®Google Scholar
• Koh AH, Chen LJ, Chen SJ, et al. Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment. Retina. 2013;33(4):686–716. doi:10.1097/IAE.0b013e3182852446
   PubMed Web of Science ®Google Scholar
• Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet. 2012;379(9827):1728–1738. doi:10.1016/S0140-6736(12)60282-7
   PubMed Web of Science ®Google Scholar
• Bhoomibunchoo C, Yospaiboon Y, Thoongsuwan S, et al. Idiopathic polypoidal choroidal vasculopathy in Thai patients with clinical and angiographic choroidal neovascularization. Clin Ophthalmol. 2017;11:317–322. doi:10.2147/OPTH.S126226
   PubMed Web of Science ®Google Scholar
• Cho HJ, Baek JS, Lee DW, Kim CG, Kim JW. Short-term effectiveness of intravitreal bevacizumab vs. ranibizumab injections for patients with polypoidal choroidal vasculopathy. Korean J Ophthalmol. 2012;26(3):157–162. doi:10.3341/kjo.2012.26.3.157
   Google Scholar
• Qian T, Li X, Zhao M, Xu X. Polypoidal choroidal vasculopathy treatment options: a meta-analysis. Eur J Clin Invest. 2018;48(1):e12840. doi:10.1111/eci.12840
   Web of Science ®Google Scholar
• Han LH, Yuan LF, Liang X, Jia X, Zhang ML. Combined therapy versus anti-vascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy: a meta-analysis. Int J Ophthalmol. 2017;10(8):1280–1289.
   Web of Science ®Google Scholar
• Koh A, Lai TY, Takahashi K, et al. Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial. JAMA Ophthalmol. 2017;135(11):1206–1213. doi:10.1001/jamaophthalmol.2017.4030
   PubMed Web of Science ®Google Scholar
• Lim TH, Lai TYY, Takahashi K, et al. Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: the EVEREST II randomized clinical trial. JAMA Ophthalmol. 2020;138(9):935–942. doi:10.1001/jamaophthalmol.2020.2443
   PubMed Web of Science ®Google Scholar
• Koh A, Lee WK, Chen LJ, et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012;32(8):1453–1464. doi:10.1097/IAE.0b013e31824f91e8
   PubMed Web of Science ®Google Scholar
• Wong CW, Cheung CM, Mathur R, et al. Three-year results of polypoidal choroidal vasculopathy treated with photodynamic therapy: retrospective study and systematic review. Retina. 2015;35(8):1577–1593. doi:10.1097/IAE.0000000000000499
   PubMed Web of Science ®Google Scholar
• Wong CW, Wong TY, Cheung CMG. Polypoidal choroidal vasculopathy in Asians. J Clin Med. 2015;4(5):782–821. doi:10.3390/jcm4050782
   PubMed Web of Science ®Google Scholar
• Sho K, Takahashi K, Yamada H, et al. Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics. Arch Ophthalmol. 2003;121(10):1392–1396. doi:10.1001/archopht.121.10.1392
   PubMedGoogle Scholar
• Dilokthornsakul P, Chaiyakunapruk N, Ruamviboonsuk P, et al. Health resource utilization and the economic burden of patients with wet age-related macular degeneration in Thailand. Int J Ophthalmol. 2014;7(1):145–151.
   PubMed Web of Science ®Google Scholar
• Working Group on the Guidelines for Health Technology Assessment in Thailand. Guidelines for Health Technology Assessment in Thailand. 1st ed. Nonthaburi, Thailand: The Graphico Systems Co., Ltd.; 2009.
   Google Scholar
• Salmon HA, Chalk D, Stein K. How lack of information hampers decision making in ophthalmology. Br J Health Care Manag. 2017;23(1):28–38. doi:10.12968/bjhc.2017.23.1.28
   Google Scholar
• Lee WK, Iida T, Ogura Y, et al. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: a randomized clinical trial. JAMA Ophthalmol. 2018;136(7):786–793. doi:10.1001/jamaophthalmol.2018.1804
   PubMed Web of Science ®Google Scholar
• Wong TY, Ogura Y, Lee WK, et al. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy: two-year results of the aflibercept in polypoidal choroidal vasculopathy study. Am J Ophthalmol. 2019;204:80–89. doi:10.1016/j.ajo.2019.02.027
   PubMed Web of Science ®Google Scholar
• LUMINOUS™: study to observe the effectiveness and safety of ranibizumab through individualized patient treatment and associated outcomes. Basel: Novartis Pharma AG; April 12, 2017.
   Google Scholar
• Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013;382(9900):1258–1267. doi:10.1016/S0140-6736(13)61501-9
   PubMed Web of Science ®Google Scholar
• Doble B, Finkelstein EA, Tian Y, et al. Cost-effectiveness of intravitreal ranibizumab with verteporfin photodynamic therapy compared with ranibizumab monotherapy for patients with polypoidal choroidal vasculopathy. JAMA Ophthalmol. 2020;138(3):251–259. doi:10.1001/jamaophthalmol.2019.5628
   Web of Science ®Google Scholar
• Feng PW, Lin J, Sakurada Y, et al. Cost and outcomes analysis of polypoidal choroidal vasculopathy (aneurysmal type 1 neovascularization) treatment strategies. J Vitreoretin Dis. 2020;5(3):227–231. doi:10.1177/2474126420946599
   Google Scholar
• The Royal College of Ophthalmologists. Drugs shortage: continuing shortage of visudyne (verteporfin); 2021. Available from: https://www.rcophth.ac.uk/2021/07/shortage-of-visudyne/. Accessed August 31, 2021.
   Google Scholar